However, using as control the reference population with a similar age range to stroke patients, no differences in the prevalence of most of these antibodies were found between both populations except for IgA aB2GPI, that was significantly higher in stroke patients (20%, n = 49) than in the reference population (6.6%, n = 8) (OR: 3.53, 95% CI: 1.61–7.72, p < 0.001). Here, CD79A is linked to stroke disorder.